The Neuro (Montreal Neurological Institute-Hospital) has joined the Douglas Research Centre (DRC) and the Canadian Open Neuroscience Platform (CONP) in signing the San Francisco Declaration on Research Assessment (DORA), an agreement that seeks to change how scholarly research contributions are valued in hiring, promotion, and funding decisions.
Since joining The Neuro in 2016, Boris Bernhardt, PhD, Assistant Professor of Neurology and Neurosurgery, has published pioneering research on the organization and development of the healthy brain. His achievements have been recognized this week by the Canadian Association for Neuroscience, who have awarded him the 2022 New Investigator Award.
Today the Douglas Research Centre (DRC) joins The Neuro’s Tanenbaum Open Science Institute (TOSI) as a partner in research data sharing and collaboration through the adoption of a set of institutional Open Science principles.
Psychedelics are now a rapidly growing area of neuroscience and clinical research, one that may produce much-needed new therapies for disorders such as depression and schizophrenia. Yet there is still a lot to know about how these drug agents alter states of consciousness.
An antibody characterization project with partners at The Neuro will be able to expand thanks to funding from Génome Québec.
The COVID-19 pandemic has presented both challenges and opportunities for medical training. Remote learning technology has become increasingly important in several fields. A new study finds that in a remote environment, an artificial intelligence (AI) tutoring system can outperform expert human instructors.
A new research collaboration between The Neuro (Montreal Neurological Institute-Hospital), Takeda Development Center Americas, Inc. and Roche will enable large-scale analysis of patient data to potentially find promising targets for drug development in neurological diseases.
To support 2021’s International Open Access Week, Pfizer commissioned Inspiring STEM Consulting to record a series of podcast interviews with experts working within clinical and medical disciplines. The objective was to share perspectives on the real-world impact and benefit of open science for patients and key stakeholders.
A new study from The Neuro (Montreal Neurological Institute-Hospital) and eight collaborating international epilepsy centers has developed a simple web-based application clinicians can use to predict which patients will not benefit from an invasive diagnostic work-up, preventing unnecessary, invasive procedures, saving time for patients and the clinical team, and freeing up overburdened health resources.
The COVID-19 pandemic has tested our psychological limits. Some have been more affected than others by the stress of potential illness and the confusion of constantly changing health information and new restrictions. A new study finds the pandemic may have also impaired people’s cognitive abilities and altered risk perception, at a time when making the right health choices is critically important.
Professor Robert Zatorre has been recognized for his work by La Fondation Pour l’Audition, a research institute and hearing advocacy organization based in Paris, France. He is this year’s recipient of the Grand Prix Scientifique, which recognizes leading research into the human auditory system.
The Neuro’s director, Dr. Guy Rouleau, has been elected first vice-president of the World Federation of Neurology. The first vice-president and other WFN officers are elected by delegates from its 122 neurological societies around the world.
The mission of the WFN is to foster quality neurology and brain health worldwide by promoting global neurological education and training with emphasis placed firmly on under-resourced parts of the world.
People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary ball, or try to run from an illusory assailant. Such actions are more than just a nuisance. People with the disorder have a 50 to 80 per cent chance of developing a serious neurodegenerative disease within a decade of diagnosis.
